Clear Search

Showing 1 result for “for the STEP 8 Investigators” published 2022.

March 2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

JAMA 2022;327(2):138–50 doi:10.1001/jama.2021.23619

Among adults with overweight or obesity without diabetes, QW SC semaglutide compared with QD SC liraglutide – added to counselling for diet and physical activity – resulted in significantly greater weight loss at 68 weeks.

more…